



Title: Workshop on “Increasing Investments for AMR R&D”

Objective: Identify and discuss opportunities for investments and new and innovative financing mechanisms for AMR R&D using a global One Health approach.

Expected Outcome: Identification and recommendations of new and innovative mechanisms and opportunities for increasing investment for AMR R&D. Recommendations on how the Global AMR R&D Hub can support these activities considering a One Health approach.

- 1) Articulate recommendations that can be tracked and followed up by the Global AMR R&D Hub
- 2) Provide a high-level summary and next steps for the Global AMR R&D Hub to the G20 Health Working Group on May 29
- 3) Share outcomes of the meeting

Format: Plenary sessions and panel discussions followed by working group discussions in a breakout session concluding with a report session.

Participants: AMR R&D Hub Members and Observers, further representatives of governments, funders, industry, other investors and other interested stakeholders.

Programme:

When: Tuesday 28 May 2019

Where: Domaine de Penthes, Geneva, Room: Espace Gallatin

Time	Title	Speaker
9:00 – 9:10	Welcome and Opening remarks Vice-Chair of Global AMR R&D Hub	Bersabel Ephrem, Canada
9:10 – 9:20	Introductory Remarks, G20 Presidency - Japan	Chieko Ikeda – Senior Assistant Minister for Global Health
9:20 – 9:40	Keynote	Dame Sally Davies – Chief Medical Officer, UK
	Plenary Session 1 – One Health	Chair: Larry Kerr – US Department of Health and Human Services
9:40 – 9:55	<u>Setting the Stage:</u> Progress to date regarding implementing incentives and funding mechanisms	Christine Årdal – Norwegian Institute of Public Health
9:55 – 10:10	Fostering investment in development of new antimicrobial treatments	Peter Beyer – WHO

10:10 – 10:25	Investing in agriculture to reduce human health externalities: a LMIC perspective	Delia Randolph – International Livestock Research Institute
10:25 – 10:40	STAR-IDAZ International Research Consortium: A Platform for Global Coordination of Animal Disease Research	Alex Morrow – STAR-IDAZ
10:40 – 10:55	Animal Health R&D: Barriers, Trends and Opportunities	Carel du Marchie Sarvaas – HealthforAnimals
10:55 – 11:15	Coffee Break	
	Plenary Session 2	Chair: Padmini Srikantiah – Bill & Melinda Gates Foundation
11:15 – 11:30	<u>Vaccines:</u> Vaccines for AMR: recommendations, challenges, and incentives	Elizabeth Klemm – Wellcome
11:30 – 11:45	<u>Diagnostics:</u> Diagnostics: status of current and novel technologies to preserve and protect existing medications	Adam Zerda – Becton Dickinson
11:45 – 12:00	<u>Non-traditional investors:</u> Financing AMR from an EIB perspective	Felicitas Riedl – European Investment Bank
12:00 – 12:45	Panel Discussion: Food for thought for the breakout session To address following questions: <ul style="list-style-type: none"> - How can international fora and especially G20 help increasing investment in AMR? - How can we leverage public-public and public-private cooperation for AMR R&D? - What are the drivers for investment in AMR R&D by different investors (public and private)? - How can involvement of private investors be strengthened? - What are the barriers for funding in areas other than (new) drug development, such as animal and environment sectors, vaccines, applicability to LMIC? - How can the work of the Global AMR R&D Hub support ongoing activities? 	Moderators: Larry Kerr – US Department of Health and Human Services and Padmini Srikantiah – Bill & Melinda Gates Foundation Panel: speakers from the plenary sessions 1 and 2
12:45 – 13:45	Lunch	
	Plenary Session 3 – Country Perspectives	
13:45 – 13:55	Strengths and weaknesses of research priorities on AMR in Europe	Chair: Marie-Cecile Ploy – EU Joint Action Antimicrobial Resistance and Healthcare-Associated Infections

13:55 – 14:05	A reimbursement model for keeping antibiotics available in Sweden	Jenny Hellman – Public Health Agency of Sweden
14:05 – 14:15	Antibiotic research and prudent use: The Swiss perspective	Pascal Strupler – Swiss Federal Office of Public Health
14:15 – 14:25	Overview of public AMR R&D investments – funding instruments for a One Health approach and LMIC	Laura Marin – Joint Programming Initiative on Antimicrobial Resistance
14:25 – 14:35	Incentivizing investments in R&D in LMICs	Sanne Wendes – Unitaaid
14:35 – 14:45	Fostering innovations addressing AMR threat, from India for global	Anand Anandkumar – Bugworks
14:45 – 14:55	Africa's place in investment and financing of AMR	Almoustapha Maiga – African Association for Research and Control of Antimicrobial Resistance
14:55 – 16:15	<p>Workshop: Breakout session for discussions in smaller groups to address following questions/objectives:</p> <ol style="list-style-type: none"> 1) <u>Human sector</u>: Where do we need to attract more investment (from new investors)? Do we need new mechanisms? How do we attract additional investments? Also include vaccines. 2) <u>Animal sector</u>: Are business models from the human sector applicable to the animal field? What is the current situation, what are the needs? Also include vaccines. 3) <u>LMIC</u>: What market economic models work in this context? Are funds/incentives in HIC applicable to LMIC? Analyse and provide suggestions for what is required in LMIC, including barriers and opportunities. 	<p>Leader</p> <p>Jean-Pierre Paccaud - Global Antibiotic Research and Development Partnership</p> <p>Delia Randolph – International Livestock Research Institute</p> <p>David Kaslow – PATH</p>
16:15 – 16:45	Coffee Break	
16:45 – 17:30	Report Session: To provide a brief summary of discussions of round tables, and areas for future consideration by the Global AMR R&D Hub.	Moderator: Secretariat Global AMR R&D Hub One speaker/table, 10 min + 5 min discussions
17:30 – 17:45	Closing Remarks	Andrea Spelberg – Federal Ministry of Education and Research, Germany
18:00 – 19:00	Networking Reception	